Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells.

Gong W, Hoffmann JM, Stock S, Wang L, Liu Y, Schubert ML, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Shiku H, Schmitt M, Sellner L.

Cancer Immunol Immunother. 2019 Jul;68(7):1195-1209. doi: 10.1007/s00262-019-02354-4. Epub 2019 Jun 8.

PMID:
31177329
2.

Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.

Schubert ML, Schmitt A, Sellner L, Neuber B, Kunz J, Wuchter P, Kunz A, Gern U, Michels B, Hofmann S, Hückelhoven-Krauss A, Kulozik A, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

BMJ Open. 2019 May 19;9(5):e026644. doi: 10.1136/bmjopen-2018-026644.

3.

Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.

Yoo HJ, Liu Y, Wang L, Schubert ML, Hoffmann JM, Wang S, Neuber B, Hückelhoven-Krauss A, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Mokhir A, Schmitt M, Sellner L.

Int J Mol Sci. 2019 May 18;20(10). pii: E2469. doi: 10.3390/ijms20102469.

4.

Shaping of CD56bri Natural Killer Cells in Patients With Steroid-Refractory/Resistant Acute Graft-vs.-Host Disease via Extracorporeal Photopheresis.

Ni M, Wang L, Yang M, Neuber B, Sellner L, Hückelhoven-Krauss A, Schubert ML, Luft T, Hegenbart U, Schönland S, Wuchter P, Chen BA, Eckstein V, Krüger W, Yerushalmi R, Beider K, Nagler A, Müller-Tidow C, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2019 Mar 20;10:547. doi: 10.3389/fimmu.2019.00547. eCollection 2019.

5.

Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells.

Wang L, Gong W, Wang S, Neuber B, Sellner L, Schubert ML, Hückelhoven-Krauss A, Kunz A, Gern U, Michels B, Hinkelbein M, Mechler S, Richter P, Müller-Tidow C, Schmitt M, Schmitt A.

Cytotherapy. 2019 May;21(5):566-578. doi: 10.1016/j.jcyt.2019.02.013. Epub 2019 Mar 23.

PMID:
30910382
6.

Identification of Boronic Acid Derivatives as an Active Form of N-Alkylaminoferrocene-Based Anticancer Prodrugs and Their Radiolabeling with 18F.

Daum S, Toms J, Reshetnikov V, Özkan HG, Hampel F, Maschauer S, Hakimioun A, Beierlein F, Sellner L, Schmitt M, Prante O, Mokhir A.

Bioconjug Chem. 2019 Apr 17;30(4):1077-1086. doi: 10.1021/acs.bioconjchem.9b00019. Epub 2019 Mar 13.

PMID:
30768258
7.

Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.

Stock S, Übelhart R, Schubert ML, Fan F, He B, Hoffmann JM, Wang L, Wang S, Gong W, Neuber B, Hückelhoven-Krauss A, Gern U, Christ C, Hexel M, Schmitt A, Schmidt P, Krauss J, Jäger D, Müller-Tidow C, Dreger P, Schmitt M, Sellner L.

Int J Cancer. 2019 Sep 1;145(5):1312-1324. doi: 10.1002/ijc.32201. Epub 2019 Feb 28.

PMID:
30737788
8.

EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).

Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P.

Bone Marrow Transplant. 2019 Jan 21. doi: 10.1038/s41409-019-0448-x. [Epub ahead of print]

PMID:
30664723
9.

Allogeneic transplantation in high-risk chronic lymphocytic leukemia: a single-center, intent-to-treat analysis.

Hoffmann A, Dietrich S, Hain S, Rieger M, Hegenbart U, Sellner L, Ho AD, Müller-Tidow C, Dreger P.

Haematologica. 2019 Jul;104(7):e304-e306. doi: 10.3324/haematol.2018.209486. Epub 2019 Jan 10. No abstract available.

10.

Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects.

Wang L, Ni M, Hückelhoven-Krauss A, Sellner L, Hoffmann JM, Neuber B, Luft T, Hegenbart U, Schönland S, Kleist C, Sill M, Chen BA, Wuchter P, Eckstein V, Krüger W, Hilgendorf I, Yerushalmi R, Nagler A, Müller-Tidow C, Ho AD, Dreger P, Schmitt M, Schmitt A.

Front Immunol. 2018 Oct 8;9:2207. doi: 10.3389/fimmu.2018.02207. eCollection 2018.

11.

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.

Tomska K, Kurilov R, Lee KS, Hüllein J, Lukas M, Sellner L, Walther T, Wagner L, Oleś M, Brors B, Huber W, Zenz T.

Sci Rep. 2018 Aug 13;8(1):12046. doi: 10.1038/s41598-018-30509-3.

12.

Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells.

Stock S, Hoffmann JM, Schubert ML, Wang L, Wang S, Gong W, Neuber B, Gern U, Schmitt A, Müller-Tidow C, Dreger P, Schmitt M, Sellner L.

Hum Gene Ther. 2018 Oct;29(10):1167-1182. doi: 10.1089/hum.2017.237. Epub 2018 Sep 5.

PMID:
30024314
13.

Connectome verification: inter-rater and connection reliability of tract-tracing-based intrinsic hypothalamic connectivity.

Schmitt O, Eipert P, Schwanke S, Lessmann F, Meinhardt J, Beier J, Kadir K, Karnitzki A, Sellner L, Klünker AC, Ruß F, Jenssen J.

Brief Bioinform. 2018 Jun 11. doi: 10.1093/bib/bby048. [Epub ahead of print]

PMID:
29897426
14.

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy.

Gdynia G, Robak T, Kopitz J, Heller A, Grekova S, Duglova K, Laukemper G, Heinzel-Gutenbrunner M, Gutenbrunner C, Roth W, Ho AD, Schirmacher P, Schmitt M, Dreger P, Sellner L.

EBioMedicine. 2018 Jun;32:125-133. doi: 10.1016/j.ebiom.2018.05.030. Epub 2018 Jun 5.

15.

Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients.

Hoffmann JM, Schubert ML, Wang L, Hückelhoven A, Sellner L, Stock S, Schmitt A, Kleist C, Gern U, Loskog A, Wuchter P, Hofmann S, Ho AD, Müller-Tidow C, Dreger P, Schmitt M.

Front Immunol. 2018 Jan 10;8:1956. doi: 10.3389/fimmu.2017.01956. eCollection 2017.

16.

Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.

17.

Lysosome-Targeting Amplifiers of Reactive Oxygen Species as Anticancer Prodrugs.

Daum S, Reshetnikov MSV, Sisa M, Dumych T, Lootsik MD, Bilyy R, Bila E, Janko C, Alexiou C, Herrmann M, Sellner L, Mokhir A.

Angew Chem Int Ed Engl. 2017 Dec 4;56(49):15545-15549. doi: 10.1002/anie.201706585. Epub 2017 Nov 9.

PMID:
28994179
18.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Andersson EI, Pützer S, Yadav B, Dufva O, Khan S, He L, Sellner L, Schrader A, Crispatzu G, Oleś M, Zhang H, Adnan-Awad S, Lagström S, Bellanger D, Mpindi JP, Eldfors S, Pemovska T, Pietarinen P, Lauhio A, Tomska K, Cuesta-Mateos C, Faber E, Koschmieder S, Brümmendorf TH, Kytölä S, Savolainen ER, Siitonen T, Ellonen P, Kallioniemi O, Wennerberg K, Ding W, Stern MH, Huber W, Anders S, Tang J, Aittokallio T, Zenz T, Herling M, Mustjoki S.

Leukemia. 2018 Mar;32(3):774-787. doi: 10.1038/leu.2017.252. Epub 2017 Aug 14.

PMID:
28804127
19.

MED12 mutations and NOTCH signalling in chronic lymphocytic leukaemia.

Wu B, Słabicki M, Sellner L, Dietrich S, Liu X, Jethwa A, Hüllein J, Walther T, Wagner L, Huang Z, Zapatka M, Zenz T.

Br J Haematol. 2017 Nov;179(3):421-429. doi: 10.1111/bjh.14869. Epub 2017 Aug 2.

PMID:
28771672
20.

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P.

Bone Marrow Transplant. 2017 Apr;52(4):656. doi: 10.1038/bmt.2017.12. No abstract available.

PMID:
28377595
21.

ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data.

Bystry V, Reigl T, Krejci A, Demko M, Hanakova B, Grioni A, Knecht H, Schlitt M, Dreger P, Sellner L, Herrmann D, Pingeon M, Boudjoghra M, Rijntjes J, Pott C, Langerak AW, Groenen PJTA, Davi F, Brüggemann M, Darzentas N; EuroClonality-NGS.

Bioinformatics. 2017 Feb 1;33(3):435-437. doi: 10.1093/bioinformatics/btw634.

PMID:
28172348
22.

GvL effects in T-prolymphocytic leukemia: evidence from MRD kinetics and TCR repertoire analyses.

Sellner L, Brüggemann M, Schlitt M, Knecht H, Herrmann D, Reigl T, Krejci A, Bystry V, Darzentas N, Rieger M, Dietrich S, Luft T, Ho AD, Kneba M, Dreger P.

Bone Marrow Transplant. 2017 Apr;52(4):544-551. doi: 10.1038/bmt.2016.305. Epub 2016 Dec 12. Erratum in: Bone Marrow Transplant. 2017 Apr;52(4):656.

PMID:
27941777
23.

Dissection of CD20 regulation in lymphoma using RNAi.

Słabicki M, Lee KS, Jethwa A, Sellner L, Sacco F, Walther T, Hüllein J, Dietrich S, Wu B, Lipka DB, Oakes CC, Mamidi S, Pyrzyńska B, Winiarska M, Oleś M, Seifert M, Plass C, Kirschfink M, Boettcher M, Gołąb J, Huber W, Fröhling S, Zenz T.

Leukemia. 2016 Dec;30(12):2409-2412. doi: 10.1038/leu.2016.230. Epub 2016 Aug 18. No abstract available.

PMID:
27560109
24.

Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.

Schubert ML, Hückelhoven A, Hoffmann JM, Schmitt A, Wuchter P, Sellner L, Hofmann S, Ho AD, Dreger P, Schmitt M.

Hum Gene Ther. 2016 Oct;27(10):758-771. doi: 10.1089/hum.2016.097. Epub 2016 Jul 31.

PMID:
27479233
25.

Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.

Sellner L, Boumendil A, Finel H, Choquet S, de Rosa G, Falzetti F, Scime R, Kobbe G, Ferrara F, Delmer A, Sayer H, Amorim S, Bouabdallah R, Finke J, Salles G, Yakoub-Agha I, Faber E, Nicolas-Virelizier E, Facchini L, Vallisa D, Zuffa E, Sureda A, Dreger P; EBMT Lymphoma Working Party.

Bone Marrow Transplant. 2016 Feb;51(2):212-8. doi: 10.1038/bmt.2015.273. Epub 2015 Nov 16.

PMID:
26569093
26.

p53-dependent non-coding RNA networks in chronic lymphocytic leukemia.

Blume CJ, Hotz-Wagenblatt A, Hüllein J, Sellner L, Jethwa A, Stolz T, Slabicki M, Lee K, Sharathchandra A, Benner A, Dietrich S, Oakes CC, Dreger P, te Raa D, Kater AP, Jauch A, Merkel O, Oren M, Hielscher T, Zenz T.

Leukemia. 2015 Oct;29(10):2015-23. doi: 10.1038/leu.2015.119. Epub 2015 May 14.

PMID:
25971364
27.

Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.

Mamidi S, Höne S, Teufel C, Sellner L, Zenz T, Kirschfink M.

Oncoimmunology. 2015 Jan 22;4(3):e979688. eCollection 2015 Mar.

28.

Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity.

Daum S, Chekhun VF, Todor IN, Lukianova NY, Shvets YV, Sellner L, Putzker K, Lewis J, Zenz T, de Graaf IA, Groothuis GM, Casini A, Zozulia O, Hampel F, Mokhir A.

J Med Chem. 2015 Feb 26;58(4):2015-24. doi: 10.1021/jm5019548. Epub 2015 Feb 9.

PMID:
25633601
29.

Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Knudsen PB, Hanna B, Ohl S, Sellner L, Zenz T, Döhner H, Stilgenbauer S, Larsen TO, Lichter P, Seiffert M.

Leukemia. 2014 Jun;28(6):1289-98. doi: 10.1038/leu.2013.360. Epub 2013 Nov 27.

PMID:
24280868
30.

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.

Jethwa A, Hüllein J, Stolz T, Blume C, Sellner L, Jauch A, Sill M, Kater AP, te Raa GD, Geisler C, van Oers M, Dietrich S, Dreger P, Ho AD, Paruzynski A, Schmidt M, von Kalle C, Glimm H, Zenz T.

Br J Haematol. 2013 Nov;163(4):496-500. doi: 10.1111/bjh.12539. Epub 2013 Aug 27.

PMID:
24032483
31.

Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells.

Marzenell P, Hagen H, Sellner L, Zenz T, Grinyte R, Pavlov V, Daum S, Mokhir A.

J Med Chem. 2013 Sep 12;56(17):6935-44. doi: 10.1021/jm400754c. Epub 2013 Aug 26.

PMID:
23931109
32.

Next-generation sequencing of cancer consensus genes in lymphoma.

Hüllein J, Jethwa A, Stolz T, Blume C, Sellner L, Sill M, Langer C, Jauch A, Paruzynski A, von Kalle C, Schmidt M, Glimm H, Zenz T.

Leuk Lymphoma. 2013 Aug;54(8):1831-5. doi: 10.3109/10428194.2013.796053. Epub 2013 Jun 14.

PMID:
23621802
33.

Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.

Sellner L, Heiss C, Benner A, Raab MS, Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H, Neben K.

Cancer. 2013 Jul 1;119(13):2438-46. doi: 10.1002/cncr.28104. Epub 2013 Apr 10.

34.

[The early expressive vocabulary size in simultaneous bilingual growing-up infants - a diagnostic relevant criterion?].

Kiese-Himmel C, Sellner L, Bockmann AK.

Gesundheitswesen. 2013 Aug;75(8-9):496-9. doi: 10.1055/s-0032-1331242. Epub 2013 Jan 4. German.

PMID:
23292966
35.

What do we do with chronic lymphocytic leukemia with 17p deletion?

Sellner L, Denzinger S, Dietrich S, Glimm H, Merkel O, Dreger P, Zenz T.

Curr Hematol Malig Rep. 2013 Mar;8(1):81-90. doi: 10.1007/s11899-012-0143-0. Review.

PMID:
23188619
36.

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Sellner L, Dietrich S, Dreger P, Glimm H, Zenz T.

Curr Hematol Malig Rep. 2012 Mar;7(1):3-12. doi: 10.1007/s11899-011-0110-1. Review.

PMID:
22237849
37.

Efficient gene transfer with pseudotyped recombinant adeno-associated viral vectors into human chronic myelogenous leukemia cells.

Sellner L, Veldwijk MR, Kleinschmidt JA, Laufs S, Topaly J, Fruehauf S, Zeller WJ, Wenz F.

Leuk Lymphoma. 2011 Mar;52(3):483-90. doi: 10.3109/10428194.2010.545460.

PMID:
21323526
38.

Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.

Sellner L, Capper D, Meyer J, Langhans CD, Hartog CM, Pfeifer H, Serve H, Ho AD, Okun JG, Krämer A, Von Deimling A.

Eur J Haematol. 2010 Nov;85(5):457-9. doi: 10.1111/j.1600-0609.2010.01505.x. No abstract available.

PMID:
20659156
39.

Pseudotyped recombinant adeno-associated viral vectors mediate efficient gene transfer into primary human CD34(+) peripheral blood progenitor cells.

Veldwijk MR, Sellner L, Stiefelhagen M, Kleinschmidt JA, Laufs S, Topaly J, Fruehauf S, Zeller WJ, Wenz F.

Cytotherapy. 2010;12(1):107-12. doi: 10.3109/14653240903348293.

PMID:
19929455
40.

Normal-tissue radioprotection by overexpression of the copper-zinc and manganese superoxide dismutase genes.

Veldwijk MR, Herskind C, Sellner L, Radujkovic A, Laufs S, Fruehauf S, Zeller WJ, Wenz F.

Strahlenther Onkol. 2009 Aug;185(8):517-23. doi: 10.1007/s00066-009-1973-0. Epub 2009 Aug 4.

PMID:
19652935
41.

Application of a haematopoetic progenitor cell-targeted adeno-associated viral (AAV) vector established by selection of an AAV random peptide library on a leukaemia cell line.

Stiefelhagen M, Sellner L, Kleinschmidt JA, Jauch A, Laufs S, Wenz F, Zeller WJ, Fruehauf S, Veldwijk MR.

Genet Vaccines Ther. 2008 Sep 12;6:12. doi: 10.1186/1479-0556-6-12.

42.

Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells.

Sellner L, Stiefelhagen M, Kleinschmidt JA, Laufs S, Wenz F, Fruehauf S, Zeller WJ, Veldwijk MR.

Exp Hematol. 2008 Aug;36(8):957-64. doi: 10.1016/j.exphem.2008.03.007. Epub 2008 May 20.

PMID:
18495326
44.

Segmental isodisomy and skewed X-inactivation resulting in haemophilia B in a female.

Sellner LN, Price PJ.

Br J Haematol. 2005 Nov;131(3):410-1. No abstract available.

PMID:
16225663
45.

Detection of mutations in the glycine decarboxylase gene in patients with nonketotic hyperglycinaemia.

Sellner L, Edkins E, Greed L, Lewis B.

Mol Genet Metab. 2005 Feb;84(2):167-71. Epub 2004 Nov 23.

PMID:
15670722
46.

MLPA and MAPH: new techniques for detection of gene deletions.

Sellner LN, Taylor GR.

Hum Mutat. 2004 May;23(5):413-9. Review.

PMID:
15108271
47.

Sarcomatoid renal cell carcinoma of papillary origin. A case report and cytogenic evaluation.

Cohen RJ, McNeal JE, Susman M, Sellner LN, Iacopetta BJ, Weinstein SL, Dawkins HJ.

Arch Pathol Lab Med. 2000 Dec;124(12):1830-2.

PMID:
11100068
48.

Distinction between intraductal carcinoma of the prostate (IDC-P), high-grade dysplasia (PIN), and invasive prostatic adenocarcinoma, using molecular markers of cancer progression.

Dawkins HJ, Sellner LN, Turbett GR, Thompson CA, Redmond SL, McNeal JE, Cohen RJ.

Prostate. 2000 Sep 1;44(4):265-70.

PMID:
10951489
49.

Variant chromophobe renal cell carcinoma.

Cohen RJ, Weinstein S, Robertson T, Sellner LN, Dawkins HJ, McNeal JE.

Arch Pathol Lab Med. 2000 Jun;124(6):904-6.

PMID:
10835533
50.

Comparison of three RT-PCR methods.

Sellner LN, Turbett GR.

Biotechniques. 1998 Aug;25(2):230-4.

Supplemental Content

Loading ...
Support Center